Galmed Pharmaceuticals annual return on equity
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Galmed Pharmaceuticals Return on Equity (ROE) Growth & History (GLMD)
Galmed Pharmaceuticals's return on equity was −64.21% for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −64.21% | −14.44 pp |
| 2024 | 2024-12-31 | −49.77% | +0.86 pp |
| 2023 | 2023-12-31 | −50.63% | +30.72 pp |
| 2022 | 2022-12-31 | −81.36% | +5.63 pp |
| 2021 | 2021-12-31 | −86.98% | −36.51 pp |
| 2020 | 2020-12-31 | −50.47% | −24.53 pp |
| 2019 | 2019-12-31 | −25.94% | −6.93 pp |
| 2018 | 2018-12-31 | −19.01% | +72.53 pp |
| 2017 | 2017-12-31 | −91.54% | +12.40 pp |
| 2016 | 2016-12-31 | −103.94% | −63.82 pp |
| 2015 | 2015-12-31 | −40.12% | +21.69 pp |
| 2014 | 2014-12-31 | −61.81% | — |
Galmed Pharmaceuticals quarterly return on equity
Q2.16
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −20.41% | −7.07 pp |
| Q1 2026 | 2026-03-31 | −12.85% | −6.20 pp |
| Q4 2025 | 2025-12-31 | −27.62% | −4.79 pp |
| Q3 2025 | 2025-09-30 | −9.55% | — |
| Q2 2025 | 2025-06-30 | −13.34% | −4.62 pp |
| Q1 2025 | 2025-03-31 | −6.65% | — |
| Q4 2024 | 2024-12-31 | −22.83% | — |
| Q2 2024 | 2024-06-30 | −8.72% | +4.57 pp |
| Q2 2023 | 2023-06-30 | −13.29% | +1.30 pp |
| Q2 2022 | 2022-06-30 | −14.58% | +4.25 pp |
| Q2 2021 | 2021-06-30 | −18.84% | −10.32 pp |
| Q2 2020 | 2020-06-30 | −8.52% | −3.59 pp |
| Q2 2019 | 2019-06-30 | −4.93% | +0.10 pp |
| Q2 2018 | 2018-06-30 | −5.03% | +26.06 pp |
| Q2 2017 | 2017-06-30 | −31.09% | −7.12 pp |
| Q2 2016 | 2016-06-30 | −23.97% | — |
Galmed Pharmaceuticals return on equity trends
Over the last five fiscal years, Galmed Pharmaceuticals's return on equity decreased from −50.47% to −64.21%, a change of −13.74 percentage points. The latest reported quarter, Q2 2026, shows −20.41%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗